|
1
|
World Health Organization, . Diffuse large
B-cell lymphoma. http://www.who.int/selection_medicines/committees/expert/20/applications/DiffuseLargeBCellLymphoma.pdf16–December.
2016
|
|
2
|
Li Y, Wang Y, Wang Z, Yi D and Ma S:
Racial differences in three major NHL subtypes: Descriptive
epidemiology. Cancer Epidemiol. 39:8–13. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer in Slovenia 2013, . Ljubljana:
Institute of Oncology Ljubljana, Epidemiology and Cancer Registry.
http://www.onko-i.si/fileadmin/onko/datoteke/dokumenti/RRS/LP_2013.pdf8–March.
2017
|
|
4
|
Cairo MS and Perkins SL: Hematological
Malignancies in Children, Adolescents and Young Adults. First
edition. World Scientific Publishing Co.; Singapore: 2012,
View Article : Google Scholar
|
|
5
|
Sehn LH and Gascoyne RD: Diffuse large
B-cell lymphoma: Optimizing outcome in the context of clinical and
biologic heterogeneity. Blood. 125:22–32. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
International Non-Hodgkin's Lymphoma
Prognostic Factors Project: A predictive model for aggressive
non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Coiffier B, Lepage E, Brier J, Herbrecht
R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G,
Gaulard P, et al: CHOP chemotherapy plus rituximab compared with
CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
N Engl J Med. 346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Habermann TM, Weller EA, Morrison VA,
Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI,
Peterson BA and Horning SJ: Rituximab-CHOP versus CHOP alone or
with maintenance rituximab in older patients with diffuse large
B-cell lymphoma. J Clin Oncol. 24:3121–3127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pfreundschuh M, Trümper L, Österborg A,
Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani
PL, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like
chemotherapy alone in young patients with good-prognosis diffuse
large-B-cell lymphoma: A randomised controlled trial by the
MabThera International Trial (MInT) Group. Lancet Oncol. 7:379–391.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gregoric B, Zadnik V and Novakovic
Jezersek B: The diffuse large B-cell lymphoma-where do we stand now
in everyday clinical practice. Radiol Oncol. 46:153–159. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E and Lister TA: Alliance,
Australasian Leukaemia and Lymphoma Group; Eastern Cooperative
Oncology Group; European Mantle Cell Lymphoma Consortium:
Recommendations for initial evaluation, staging, and response
assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano
classification. J Clin Oncol. 32:3059–3068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sehn LH, Berry B, Chhanabhai M, Fitzgerald
C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J,
et al: The revised international prognostic index (R-IPI) is a
better predictor of outcome than the standard IPI for patients with
diffuse large B-cell lymphoma treated with R-CHOP. Blood.
109:1857–1861. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coiffier B, Thieblemont C, Van Den Neste
E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M,
Sebban C, et al: Long-term outcome of patients in the LNH-98.5
trial, the first randomized study comparing rituximab-CHOP to
standard CHOP chemotherapy in DLBCL patients: A study by the Groupe
d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Purroy N, Bergua J, Gallur L, Prieto J,
Lopez LA, Sancho JM, García-Marco JA, Castellví J, Montes-Moreno S,
Batlle A, et al: Long-term follow-up of dose-adjusted EPOCH plus
rituximab (DA-EPOCH-R) in untreated patients with poor prognosis
large B-cell lymphoma. A phase II study conducted by the Spanish
PETHEMA Group. Br J Haematol. 169:188–198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Holte H, Leppä S, Björkholm M, Fluge O,
Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML,
Erlanson M, Kolstad A, et al: Dose-densified chemoimmunotherapy
followed by systemic central nervous system prophylaxis for younger
high-risk diffuse large B-cell/follicular grade 3 lymphoma
patients: Results of a phase II Nordic Lymphoma Group study. Ann
Oncol. 24:1385–1392. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schmitz N, Nickelsen M, Ziepert M, Haenel
M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G,
et al: Conventional chemotherapy (CHOEP-14) with rituximab or
high-dose chemotherapy (MegaCHOEP) with rituximab for young,
high-risk patients with aggressive B-cell lymphoma: An open-label,
randomised, phase 3 trial (DSHNHL 2002–1). Lancet Oncol.
13:1250–1259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fitoussi O, Belhadj K, Mounier N, Parrens
M, Tilly H, Salles G, Feugier P, Ferme C, Ysebaert L, Gabarre J, et
al: Survival impact of rituximab combined with ACVBP and upfront
consolidation autotransplantation in high-risk diffuse large B-cell
lymphoma for GELA. Haematologica. 96:1136–1143. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tilly H, da Silva Gomes M, Vitolo U, Jack
A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW,
Pfreundschuh M, et al: Diffuse large B-cell lymphoma (DLBCL): ESMO
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 5 Suppl 26:v116–v125. 2015. View Article : Google Scholar
|
|
19
|
Le Gouill S, Milpied JN, Lamy T, Delwail
V, Gressin R, Guyotat D, Damaj GL, Foussard C, Cartron G,
Maisonneuve H, et al: First-line rituximab (R) high-dose therapy
(R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell
lymphoma: Preliminary results of the GOELAMS 075 prospective
multicenter randomized trial. J Clin Oncol. 29 Suppl 15:S80032011.
View Article : Google Scholar
|
|
20
|
Wilson WH, Young RM, Schmitz R, Yang Y,
Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano
J, et al: Targeting B cell receptor signalling with ibrutinib in
diffuse large B cell lymphoma. Nat Med. 21:922–926. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hong JY, Suh C and Kim WS: Evolution of
frontline treatment of diffuse large B-cell lymphoma: A brief
review and recent update. F1000Res. 5:pii: F1000 Faculty Rev-1933.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stephens DM, Li H, LeBlanc ML, Puvvada SD,
Persky D, Friedberg JW and Smith SM: Continued risk of relapse
independent of treatment modality in limited-stage diffuse large
B-cell lymphoma: Final and long-term analysis of Southwest Oncology
Group Study S8736. J Clin Oncol. 34:2997–3004. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Olszewski AJ, Winer ES and Castillo JJ:
Validation of clinical prognostic indices for diffuse large B-cell
lymphoma in the national cancer data base. Cancer Causes Control.
26:1163–1172. 2015. View Article : Google Scholar : PubMed/NCBI
|
